Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer. The study will evaluate the efficacy and safety of nintedanib combined with radiotherapy and chemotherapy (gemcitabine or capecitabine monotherapy). The primary endpoint of this study is the 1-year local control rate (LCR).

NCT Number	NCT07386704
Lead Sponsor	Peking University First Hospital
Conditions	Pancreatic Cancer Non-resectable
Enrollment	30 participants
Start Date	2025-12-09
Primary Completion	2026-12-09 (estimated)
Study Completion	2027-12-09 (estimated)
Updated on ClinicalTrials.gov	2026-02-04